** Shares of drug developer Cytokinetics CYTK.O rise ~3% to $36.24 premarket
** Co reported Q2 revenue of $66.8 million , compared with $0.2 million a year ago, helped by $52.4 million payment related to co's licensing deal for experimental heart disease drug, aficamten, in Japan with Germany's Bayer BAYGn.DE
** Co says it is on track for meeting with U.S. FDA in September ahead of potential U.S. approval of aficamten to treat obstructive hypertrophic cardiomyopathy (oCHM)
** There is "truly palpable excitement and anticipation" for launch of aficamten in early 2026 following potential FDA approval by December 26, H.C.Wainwright analysts say
** oCHM is a condition that makes heart muscles stiff and can cause cardiac arrest
** As of June 30, co had ~$1.0 billion in cash, cash equivalents and investments, CYTK says
** Up to last close, stock down 25% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.